Trial Profile
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cisplatin (Primary) ; Domvanalimab (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Zimberelimab (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms TROPHY U-01
- Sponsors Gilead Sciences; Immunomedics
- 06 Jun 2023 Results assessing efficacy outcomes in cohort 1-3 by Trop-2 archival tumor expression, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (n=113; as of 26 July 2022) of a safety analysis by UGT1A1 status of cohort 1 of this phase 2 study at median follow-up of 10.5 month presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology